Shenzhen Kangzhe Biotechnology Co., Ltd.
Clinical trials sponsored by Shenzhen Kangzhe Biotechnology Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill CMS-D017 enters first human safety trials Results expected Nov 2026 (estimated)
- Radioactive tracer tracks an experimental Drug's journey through the body Results expected Dec 2026 (estimated)
- New pill could ease heavy periods from fibroids Results expected Jan 2027 (estimated)
-
New Weight-Loss shot enters first human safety trial
Disease control Not yet recruitingThis early-stage study tests an experimental drug called CMS-D008 in 110 healthy and overweight or obese adults. The main goal is to check safety and how the body processes the drug, not weight loss. Participants will receive either the drug or a placebo as injections, and resear…
Phase 1 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Radioactive tracer tracks an experimental Drug's journey through the body
Knowledge-focused Not yet recruitingThis Phase 1 study in China gives a single oral dose of a radiolabeled experimental drug, [14C] CMS-D002, to healthy adults aged 18-45. Researchers will measure how much of the drug is recovered in urine and feces, how it moves through the blood, and what breakdown products it fo…
Phase 1 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC